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From a statistical perspective, because the normal B-cell repertoire is so vast, lymphoma-derived idiotypes defined by anti-ids should be equally as diverse if the entire B-cell pool is at risk and neoplastic transformation is a random event. On the other hand, if the lymphoma precursor pool at risk during lymphomagenesis is restricted in any way, this might be reflected in a bias in favor of certain lymphoma idiotypes. To examine the question of idiotypic bias in human lymphoma, we have prepared a library of mouse monoclonal anti-ids derived from lymphoma-associated Ig. We have previously reported the results with our initial anti-id panel in the definition of clonal tumor cell heterogeneity as evidenced by id ~a r i a t i o n .~ In this report we had available an expanded version of our original panel and selected certain anti-ids based on their ability to detect highly restricted or "private" idiotypes. These antibodies were used to determine the extent and nature of crossreactivity with randomly selected lymphoma Ig idiotypes. Despite the restricted nature of the specificity of our anti-ids, we found a striking degree of idiotypic crossreactivity with a wide range of follicular center cell lymphoma histologic categories.
MATERIALS AND METHODS
Our procedure for obtaining Ig from secretory lymphoma heterohybridomas has been described previously! Briefly, fresh tumor cell suspensions were fused with nonsecretory NS-1 mouse myeloma cells. The resulting Preparation of lymphoma idwtypes. expression. If there was a segregated staining pattern, it was generally related to the presence of CD3+ T cells in the section. These follicular center cell-derived anti-ids crossreacted with follicular center cell tumors of all histologic grades with frequencies ranging from 13% to 50%. The structural basis for the crossreactivity of our lymphoma-derived private anti-ids is as yet not known. However, the reactivity of certain anti-ids with both kappa-and lambda-expressing tumors suggests a biased use of V gene segments in these crossreactive clones that is probably related to the VH gene.
These data suggest the possibility that lymphoma may develop in a highly restricted pool of normal differentiated B cells or in B-cell subsets that express a limited repertoire of unmutated VH gene segments.
o 1992 by The American Society of Hematology. secretory heterohybridomas were screened by enzyme-linked immunosorbent assay (ELISA) for Ig production and those secreting Ig of the same H chain class and L chain type as the parent tumor were selected and expanded. Proof of tumor origin was further obtained by matching of heterohybridoma Ig gene rearrangement pattern on Southern analysis with that of the parent tumor. Lymphoma-derived Ig was purified from supernatants by affinity chromatography.
BALBIc mice were immunized with affinity-purified tumor idiotypes as reported previously! Three days after the final injection, spleen cells were procured and fused with mouse NS-1 cells to obtain hybridomas.
A description of our methods for screening and identifying anti-idiotypes has been detailed in a prior publication! In our initial screening procedure, supernatants from secretory hybrid clones were tested by ELISA for reactivity against the immunizing tumor idiotype(s) as well as a panel of seven Ig idiotypes isolated from other lymphoma patients. This panel contained idiotypes with k, a, K, and A chain constant regions. Antibodies exhibiting strong (at least 15 times control values) reactivitywith tumor idiotypes but no reactivity with the panel were selected. These antibodies were then confirmed to exhibit anti-idiotypic specificity in flow cytometric analysis by (1) their reaction with cell surface Ig in previously frozen original tumor cell suspensions, (2) the failure to block idlanti-id reactivity with normal human serum, and (3) their lack of reactivity with normal blood lymphocyte cell suspensions. As a final confirmation, anti-ids at concentrations ranging from 2 to 10 kg/mL were shown by immunoperoxidase technique to react with the vast majority of identifiable tumor cells in frozen tissue sections of parent tumor, and react with less than 1% of normal control tonsillar lymphocytes at identical antibody concentrations. We further characterized the specificity of our anti-ids into two broad categories, shared and private, as follows? Anti-ids were tested in an ELISA assay at a concentration of 2 kg/mL for reactivity with pools of normal and neoplastic human Igs that included a pool of 15 normal sera, pools of affinity purified IgG, IgA, and IgM, a pool of 10 to 15 IgM Waldenstrom's proteins, and a pool of K and A Bence Jones proteins. Anti-ids exhibiting no reactivity whatsoever with any of these pools or normal tonsillar lymphocytes were classified as detecting private idiotopes. Anti-ids that reacted to a minor degree with the normal Ig pool and/or tonsil cells were characterized as detecting shared idiotopes. The degree of binding of anti-ids to shared idiotopes was measured in a sensitive ELISA assay. The binding of F(ab'h anti-id to normal human serum Ig was quantified by comparison with a known standard binding curve. Anti-ids detecting shared determinants in our library reacted with less than 10 kg/mL of idiotype in pooled normal human serum. In this study, we only used those anti-ids that detected private idiotopes.
Anti-ids for the tissue section staining experiments were used either as affinity purified antibodies or supernatants dialyzed against buffered NaC1. The Br 6, Mi 12, Con 4, and Ke 3 antibodies were also available as affinity purified F(ab')z fragments. These reagents were titered at dilutions that gave optimal staining with the original tumor and negative staining of controls.
Lymphoma tissue biopsies have systematically been frozen and stored in either the Lymphocyte Phenotyping Lab or the Pathology Department of the New England Medical Center Hospital since 1984. Cases were selected for study based solely on the availability of sufficient frozen tumor to perform the necessary studies. In 72 cases there was sufficient tissue, and routine histologic stains and an immunologic phenotype were also available on the original fresh specimen. No attempt was made to select cases for study based on the histologic category of lymphoma. All lymphomas were classified according to the New Working Formulation,6 were derived from the B-cell lineage, and expressed an intact SIg of known phenotype.
Tissue sections were stained using standard avidin-biotin immunoperoxidase technique (Vector Labs, Burlingame, CA).' To facilitate the experiments, each biopsy was stained initially with seven individual pools of anti-ids, each containing from 3 to 10 individual antibodies. Each biopsy was also stained with the following positive and negative controls: anti-CD3, K, A, Mi 23.6 (an irrelevant anti-id), and normal human tonsil. There was a separate control tonsil stained for each individual anti-id and/or pool. When a biopsy reacted with 1 or more of the pools, the experiment, including all controls, was repeated for each individual anti-id in the pool. Staining results were initially determined independently by A.L. and R.A.R. and reviewed subsequently by R.D.
Lymphoma tissue.

RESULTS
Characterization of anti-idiotype antibodies.
We have generated approximately 75 antibodies against lymphoma Ig procured from our first seven tumor fusions that are anti-idiotypic. Thirty-six of these anti-ids gave no reaction whatsoever with normal human serum and our various Ig pools and controls, and thus react with highly private idiotypic determinants. The remaining 39 detected shared idiotopes. In this study we have examined lymphoma biopsies for reactivity with only the 36 private reacting antibodies. The characteristics of the seven lymphomas from which our anti-id panel was originally derived are listed in Table 1 . The original tumors were follicular center cell lymphomas of both low and intermediate grades but the Mu tumor was an aggressive diffuse large cell lymphoma. These B-cell tumors expressed either p or y heavy chain isotypes and a single biclonal tumor expressed both CI. and y membrane heavy chains (described in detail in a previous p~blication). ~ We examined a total of 72 lymphoma biopsies with the 36 private reacting anti-ids derived from the seven tumors. In each case there was no reactivity with control tonsil tissue (Fig 1D) . However, 12 of 72 (17%) lymphomas reacted with one or more of our original seven antibody pools at equivalent antibody concentrations. In 11 cases we were able to repeat staining with individual antibodies contained in the positive pools to determine which individual antibodies were responsible for the reactivity. Insufficient tissue was available to Reactivity of anti-ids with lymphoma. Table 2 and ranged from 1.4% to 8.3%.
A listing of individual tumor biopsies and reactive antibodies is given in Table 3 . Br-derived anti-ids exhibited the highest degree of reactivity, detecting 9 of 12 positive tumors. In seven of these nine cases, only Br antibodies crossreacted; in two other tumors, additional anti-ids re- For personal use only. on November 15, 2017. by guest www.bloodjournal.org From acted. A similar result was obtained with Cou antibodies that detected 4 and perhaps 5 (contained in unbroken pool 7, case no. 22) of the 12 crossreacting tumors. In two tumors, only Cou anti-ids detected a shared id, and in another three cases, anti-ids derived from other tumors were reactive as well. The Con-, Ke-, and Mi-derived anti-ids crossreacted to a lesser degree, staining either one or two tumors but always in conjunction with reactivity of Br and Cou antibodies. Anti-ids derived from the Tr and Mu tumors did not stain any of the lymphomas tested.
It is of interest that, although the majority of lymphoma biopsies (9 of 12) stained with anti-ids derived from a single tumor, three cases (no. 21,22, and 47) reacted with anti-ids derived from multiple tumors. These data suggest that private idiotopes are commonly shared among lymphoma and indicate the possibility of conservation and interrelationship between the multiple crossreactive determinants. It is noteworthy that construction of a pool of five of our individual anti-ids derived from three of the seven tumors (Br 14,38, Cou 7,13, Con 16) would have detected 11 of the 12 positive cases.
Each of the 12 reactive tumors listed in Table 3 was evaluated on several occasions for SIg light chain expression by flow cytometry and frozen tissue immunoperoxidase staining, with concordant results. Four of the tumors expressed A light chains and eight expressed K light chains. The Br 38 and Cou 7 anti-ids that reacted with more than one biopsy detected idiotypes on lambda expressing as well as kappa expressing tumors, suggesting that anti-id reactivity was not related to V, or Vk gene-encoded regions. On the other hand, the Con 16 and Cou 13 anti-ids that detected shared ids on two tumors, reacted with only A expressing tumors.
Our anti-id panel was originally constructed from lymphoma idiotypes derived from follicular center cell tumors representing varying degrees of biologic aggressiveness. When this panel was reacted with the 72 biopsies, the degree of crossreactivity as a function of histologic subcategory varied from 13% to 50%. (Table 4) . We successfully stained most low-and intermediate-grade lymphoma variants. Our reagents detected ll of 58 (19%) of low-and intermediate-grade variants compared with 1 of 14 (7%) of high-grade variants. We have recently tested four additional large cell lymphomas that were also unreactive with the 36 antibodies used in this study. In either case, these differences have not reached statistical significance (two-sided test, P = .28).
It should also be noted that our antibodies have reacted with only one of eight (1 of 12) large-cell lymphomas and that the large-cell lymphoma-derived Mu antibody family has been totally unreactive with all lymphomas tested thus far. This result may merely reflect sampling bias or failure to make antibodies directed against low-frequency shared idiotopes. An alternative possibility is that shared idiotopes are lost with clonal progression and transformation to a more aggressive cell type. Hopefully, this distinction can be made based on structural studies currently in progress. Finally, we examined the staining of follicular center cell variants versus the two nonfollicular center cell variantsLymphoma histologic considerations. The extent of crossreactivity of anti-ids with a given tumor cell population can be estimated from the pattern of staining. To assess the percentage of tumor cells stained in the various histologic categories, each section stained with a pool or individual anti-id was compared with the corresponding section stained with CD3 for T cells and the appropriate L chain reagent to delineate tumor cells. By comparing these sections, one could judge whether cells not stained by anti-id were T cells, residual B cells, or unreactive tumor cells. All of our cases contained between 20% and 90% CD3 positive cells. Without exception, tumor cell staining was generally diffuse and uniform within the tumor cell population. If the overall anti-id staining was heterogeneous, it was in each case attributable to the presence of T cells in the lesion. The intensity of staining in the positive cases was also striking. In each case the intensity was quite bright without significant variation. Examples of staining patterns of both highand low-grade lymphoma are seen in Fig lA, B , and C. The more or less uniform expression of crossreactive determinants within a given tumor cell population suggests that gross alteration in the structural unit responsible for crossreactivity is not a widespread occurrence in the tumors we examined.
Staining pattems of individual tumors.
DISCUSSION
In this study we have used private reacting anti-id antibodies as probes to detect crossreactive determinants of For personal use only. on November 15, 2017. by guest www.bloodjournal.org From B-cell lymphoma-associated Igs. The antibodies we used were selected from our library based on a stringent definition of idiotype that required no detectable crossreactivity with idiotypes present in normal pools of Igs. Theoretically, these antibodies should define highly restricted antigens that could be lymphoma-specific because they detect highly private idiotopes. Selection of anti-ids based on their crossreactivity with the normal Ig pool potentially broadens, to varying degrees, the definition of idiotype to include more public or shared determinants. The latter type of anti-id panel was prepared from low-grade follicular lymphoma by Idec Corp (Mountain View, CA) and others as part of a strategy directed at creating a broad treatment directed antibody library.5vs Crossreactivity of this panel with human lymphoma and CD5+ chronic lymphocytic leukemia, ranging from 30% to 33%, was recently reported by Swisher et aL9 It is noteworthy that in the original report by Miller et a1,5 none of the 10 anti-ids that failed to react with normal human serum (private anti-ids) stained the 50 lymphomas tested.
Despite the highly restricted nature of our anti-id panel, we were able to show crossreactivity of 17% with 72 unselected lymphoma biopsies. Because we examined highly private idiotopes for crossreactivity, one would expect the frequency of finding shared-lymphoma ids to be lower than the series reported by Swisher et aL9 Even at this level, this degree of crossreactivity among lymphoma idiotypes as defined by our private anti-ids strongly suggests that the normal B-cell pool at risk for lymphomagenesis may be restricted. Thus, the bias in favor of certain idiotypes we show here could reflect transformation of certain specific subsets of differentiated B-cell clones, or suggest that lymphomas may develop in B-cell subsets that express a rather limited repertoire of unmutated gene segments. The latter mechanism of bias has been described to occur in certain autoantibodieslOJ1 and has been recently reviewed by Inghirami et a1.12 This question can be answered more precisely when genetic structural data become available.
The structural basis for the crossreactivity shown here remains to be proven because idiotypic properties may be related to H chain, L chain, both H and L chain, or framework determinants. However, because many of our crossreactive anti-ids clearly detect idiotypes present on lymphomas expressing either K or A light chains, it seems most likely that at least some of the crossreactivity we show is related to VH related sequences rather than light chain sequences. This is in contrast to the initial series of reports by Carson The anti-ids used in this study were derived from B-cell lymphoma of varying degrees of biologic aggressiveness that share a common origin and are grouped under the heading of follicular center cell tumors. The two additional highgrade B-cell variants, immunoblastic and lymphoblastic lymphoma, are not generally considered to be of follicular center cell origin. Our panel of follicular center cell-derived antibodies reacted with the major follicular center cell variants but did not crossreact with the small number of nonfollicular center cell types tested. A definitive result requires a larger series of lymphomas, but it is possible that our panel of anti-ids could be detecting determinants common to follicular center cell lymphoma that may not be expressed by these other variants. If this observation is confirmed, antibodies detecting these private idiotopes would be potentially important diagnostic reagents.
With respect to the treatment of B-cell lymphoma, our observations also have important implications. We have been able, with an initial anti-id library of only 75 antibodies, to define five anti-ids that will detect shared private ids in 15% to 17% of human B-cell lymphoma. It seems likely that with a more extensive library, this percentage will increase. If so, anti-ids detecting private determinants have certain advantages as therapeutic agents because they are theoretically highly specific and exhibit no crossreactivity with the normal B-cell pool or normal serum Igs. Furthermore, the staining patterns in our positive cases clearly show diffuse expression of id within the tumor cell population in each case and suggest strong uniform expression of crossreactive determinants. Although we and others have documented id variation within tumor cell populations, in our experience, this variation was minimal in our early untreated cases. 4 If, in fact, our shared private idiotypes represent sequences that are less prone to mutation, they would, therefore, be ideal candidates for monoclonal antibody directed therapy.
